We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+30.04%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$647M
AUM Growth
-$1.41M
Cap. Flow
-$92.7M
Cap. Flow %
-14.32%
Top 10 Hldgs %
48.48%
Holding
76
New
6
Increased
14
Reduced
49
Closed
5

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$17.1M
2
BMY icon
Bristol-Myers Squibb
BMY
+$13.1M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$8.98M
4
EPRS
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
+$6.6M
5
HRTX icon
Heron Therapeutics
HRTX
+$6.43M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$33.6M
2
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$31.8M
3
TPST icon
Tempest Therapeutics
TPST
+$12.9M
4
PBYI icon
Puma Biotechnology
PBYI
+$11.3M
5
KITE
Kite Pharma, Inc.
KITE
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 72.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBPO
26
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$7.31M 1.13%
76,500
-13,500
-15% -$1.01M
AGEN
27
Agenus
AGEN
$324M
$7.23M 1.12%
71,789
+31,029
+76% +$3.1M
FWP
28
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$7.22M 1.12%
36,429
+15,000
+70% +$2.43M
SGMO
29
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$6.93M 1.07%
442,000
-58,000
-12% -$897K
CHRS icon
30
Coherus Oncology
CHRS
$224M
$6.7M 1.04%
219,130
-3,070
-1% -$79.3K
XLRN
31
DELISTED
Acceleron Pharma
XLRN
$6.47M 1%
170,000
-80,000
-32% -$3.18M
RARE icon
32
Ultragenyx Pharmaceutical
RARE
$2.46B
$6.33M 0.98%
102,000
-18,000
-15% -$1,000K
CRIS icon
33
Curis
CRIS
$8.85M
$6.32M 0.98%
1,316
+1,016
+339% +$4.9M
ARRY
34
DELISTED
Array Biopharma Inc
ARRY
$6.26M 0.97%
850,000
-150,000
-15% -$1.07M
BCRX icon
35
BioCryst Pharmaceuticals
BCRX
$2.31B
$6.14M 0.95%
680,000
-120,000
-15% -$1.24M
SCTL
36
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$5.95M 0.92%
731,336
-49,164
-6% -$196K
APTO
37
DELISTED
Aptose Biosciences, Inc.
APTO
$5.83M 0.9%
2,404
-3
-0.1% -$7.25K
KITE
38
DELISTED
Kite Pharma, Inc.
KITE
$5.77M 0.89%
100,000
-155,000
-61% -$10.4M
NERV icon
39
Minerva Neurosciences
NERV
$203M
$5.72M 0.88%
143,130
+121,255
+554% +$5.02M
IOVA icon
40
Iovance Biotherapeutics
IOVA
$1.94B
$5.14M 0.8%
+424,815
New +$4.78M
EPZM
41
DELISTED
Epizyme, Inc
EPZM
$5M 0.77%
+266,250
New +$5.5M
LPCN icon
42
Lipocine
LPCN
$17.9M
$4.6M 0.71%
+39,216
New +$4.26M
NKTR icon
43
Nektar Therapeutics
NKTR
$2.47B
$4.37M 0.68%
26,500
-3,500
-12% -$719K
GEVA
44
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$4.14M 0.64%
42,500
-57,500
-58% -$6.09M
DRNA
45
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$4.08M 0.63%
170,000
-30,000
-15% -$675K
CBIO
46
Crescent Biopharma
CBIO
$586M
$3.82M 0.59%
4,590
-133
-3% -$103K
GNVC
47
DELISTED
GenVec, Inc.
GNVC
$3.73M 0.58%
126,284
-6,646
-5% -$218K
RMTI icon
48
Rockwell Medical
RMTI
$28.7M
$3.72M 0.57%
3,091
-545
-15% -$638K
DARE icon
49
Dare Bioscience
DARE
$20.1M
$3.62M 0.56%
3,345
-405
-11% -$392K
TLPH icon
50
Talphera
TLPH
$70.1M
$3.28M 0.51%
42,500
-7,500
-15% -$981K
1
2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q1 2015 Portfolio in Review

As of Q1 2015, Cormorant Asset Management held 76 positions worth $647M, down 0.22% from $649M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Cormorant Asset Management withdrew a net $92.7M in Q1 2015, closing 5 positions and reducing 49 holdings. Its most notable exit was Celgene Corp, an estimated $33.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 69% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Epizyme, Inc worth $5M.

  • Cormorant Asset Management's largest Q1 2015 buy was Epizyme, Inc: 266,250 shares worth $5M.
  • Cormorant Asset Management added most to Alkermes in Q1 2015, an estimated $17.1M increase.
  • Cormorant Asset Management's biggest Q1 2015 reduction was RECEPTOS INC COM STK (DE), cutting an estimated $31.8M.
  • Cormorant Asset Management fully exited Celgene Corp in Q1 2015, selling an estimated $33.6M.
  • Cormorant Asset Management's ten largest holdings make up 48% of its $647M portfolio in Q1 2015.
  • Cormorant Asset Management opened 6 new positions and closed 5 in Q1 2015.
  • Cormorant Asset Management's portfolio value fell 0.22% quarter-over-quarter to $647M.

Based on Cormorant Asset Management's 13F filing for Q1 2015, filed 15 May 2015.